Cellectis: Four Prominent Physicians to Join Cellectis Clinical Advisory Board
January 23 2017 - 4:30PM
Business Wire
New Board Members Include Professors John
Gribben, Koen van Besien, Kanti Rai and Catherine
Thieblemont
Regulatory News:
Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS; Nasdaq:
CLLS), a biopharmaceutical company focused on developing
immunotherapies based on gene edited CAR T-cells (UCART), today
announced that four new members joined Cellectis’ Clinical Advisory
Board (CAB). The CAB serves as a strategic resource to Cellectis as
the Company enters the clinical development of allogeneic CAR T
immunotherapies lead by its wholly owned product candidate,
UCART123.
The CAB initially comprises Pr John Gribben, Lead of the Centre
for Hemato-Oncology, Barts Cancer Institute of London, UK; Pr Koen
van Besien, Director of the Stem Cell Transplant Program and
Professor of Medicine at Weill Cornell Medical College, NYC, USA;
Pr Kanti Rai, Professor of Medicine and Molecular Medicine, Hofstra
Northwell School of Medicine, Hempstead, USA and Pr Catherine
Thieblemont, Professor of Hematology in the Paris VII- University,
France and Head of the Hemato-Oncology Unit of St-Louis Hospital in
Paris.
"We are honored that these leaders have agreed to join
Cellectis’ Clinical Advisory Board as forward-thinking experts,
innovators and visionaries in their respective fields,” said Dr.
Loan Hoang-Sayag, Chief Medical Officer, Cellectis. “Professors
Gribben, van Besien, Rai and Thieblemont are strong supporters of
Cellectis’ allogeneic, ‘off-the-shelf’ approach to developing
immunotherapies. The in-depth experience of these leading
physicians across the hematologic malignancies / stem cell
transplant, immunotherapy and hematology-oncology clinical research
fields will greatly inform our ongoing work to address the unmet
needs of different patient populations globally.”
Professor Gribben holds the Gordon Hamilton Fairley Chair of
Medical Oncology at St. Bartholomew's Hospital, Barts Cancer
Institute, Queen Mary, University of London, where his research
group is currently focused on immunological approaches to the
treatment of hematological cancers. He was a research fellow at
University College London and Dana-Farber Cancer Institute, Harvard
Medical School. He joined the faculty at Harvard Medical School,
the Dana-Farber Cancer Institute and Brigham and Women's Hospital
in 1992. He is a founding member of the CLL Research Consortium,
was Associate Editor of Blood from 2008-2014 and was elected a
Fellow of the Academy of Medical Science. He will be
President–Elect of The European Hematology Association (EHA) from
2017 to 2019.
Professor van Besien serves as Director of the Stem Cell
Transplant Program at Weill Cornell Medical Center and is an
Attending Physician at New York Presbyterian Hospital. A graduate
of the College ND de la Paix in Namur, Belgium, and University of
Leuven, Belgium. Professor van Besien also holds a PhD from the
University of Maastricht in the Netherlands. He completed a
hematology/oncology fellowship at Indiana University and in Bruges,
Belgium, and was a faculty member of the transplant program at MD
Anderson Cancer Center. The Professor also directed the transplant
program at the University of Illinois and the transplant and
lymphoma programs at the University of Chicago. He is
Editor-in-chief of Leukemia and Lymphoma.
Professor Rai, an internationally renowned leukemia researcher
and hematologist, brings extensive knowledge and experience from
his 50-year career spanning groundbreaking clinical leukemia
research. He is the Joel Finkelstein Cancer Foundation Professor of
Medicine at the Hofstra North Shore-LIJ School of Medicine, where
he is also Professor of Molecular Medicine. He is currently Chief
of the Chronic Lymphocytic Leukemia (CLL) Research and Treatment
Program at Northwell Cancer Institute and an Investigator at The
Feinstein Institute for Medical Research.
Professor Thieblemont is Professor of Hematology in the Paris
VII- University, France, and Head of the Hemato-Oncology Department
in the Hospital Saint-Louis – Paris, France, where she develops
specific therapeutic programs for refractory/relapsed lymphomas and
chronic lymphocytic leukemia. She belongs to the administrative and
scientific committees of the LYSA, the lymphoma study association,
to the board of directors of the IELSG, the International
extranodal lymphoma study association, and to the Fellowships and
Grants Committee of The European Hematology Association (EHA).
“As Cellectis is expected to start the world’s first clinical
trial to ever use an allogeneic CAR T therapy in the U.S., the
Company’s Clinical Advisory Board will greatly guide us in moving
full steam ahead,” added Dr. Hoang-Sayag. “The goal is that the
allogeneic CAR T cell approach will lead to a drug that is
cost-effective, easily distributed across all geographies and
immediately available to patients in need. We are thrilled to have
Professors Gribben, van Besien, Rai and Thieblemont onboard as we
inch closer to reaching this monumental milestone for cancer
patients everywhere and revolutionizing cancer treatment as we know
it today.”
About Cellectis
Cellectis is a biopharmaceutical company focused on developing
immunotherapies based on gene edited CAR T-cells (UCART). The
company’s mission is to develop a new generation of cancer
therapies based on engineered T-cells. Cellectis capitalizes on its
17 years of expertise in genome engineering - based on its flagship
TALEN® products and meganucleases and pioneering electroporation
PulseAgile technology - to create a new generation of
immunotherapies. CAR technologies are designed to target surface
antigens expressed on cells. Using its life-science-focused,
pioneering genome-engineering technologies, Cellectis’ goal is to
create innovative products in multiple fields and with various
target markets. Cellectis is listed on the Nasdaq market (ticker:
CLLS) and on the NYSE Alternext market (ticker: ALCLS). To find out
more about us, visit our website: www.cellectis.com
Talking about gene editing? We do it. TALEN® is a registered
trademark owned by the Cellectis Group.
Disclaimer
This press release contains “forward-looking” statements that
are based on our management’s current expectations and assumptions
and on information currently available to management.
Forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause our actual results,
performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by
the forward-looking statements. The risks and uncertainties
include, but are not limited to, the risk that the preliminary
results from our product candidates will not continue or be
repeated, the risk of not obtaining regulatory approval to commence
clinical trials on the UCART product candidates, the risk that any
one or more of our product candidates will not be successfully
developed and commercialized. Further information on the risks
factors that may affect company business and financial performance,
is included in filings Cellectis makes with the Security Exchange
Commission from time to time and its financial reports. Except as
required by law, we assume no obligation to update these
forward-looking statements publicly, or to update the reasons
actual results could differ materially from those anticipated in
the forward-looking statements, even if new information becomes
available in the future.
# # #
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170123006009/en/
For further information:Media
contacts:CellectisJennifer Moore, 917-580-1088VP of
Communicationsmedia@cellectis.comorKCSA Strategic
CommunicationsCaitlin Kasunich,
212-896-1241ckasunich@kcsa.comorIR contact:CellectisSimon
Harnest, 646-385-9008VP of Corporate Strategy and
Financesimon.harnest@cellectis.com
Cellectis (NASDAQ:CLLS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cellectis (NASDAQ:CLLS)
Historical Stock Chart
From Apr 2023 to Apr 2024